勃起不全の治療のための新しい埋め込み型デバイスの安全性と忍容性
根治的前立腺切除術後の勃起不全の治療のための新しい埋め込み型デバイスの安全性と忍容性
The goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy.
The main questions it aims to answer are:
- Is the device safe?
- Does the device works well? Are the participants satisfied with the device?
Participants will be implanted with the device during the ongoing prostatectomy surgery and will be asked to complete the following tasks during 6 months follow-up:
- Come to the hospital for follow-up visits,
- Complete questionnaires,
- Activate the device every day,
- Measure erection hardness.
Researchers will compare an implanted group (participants having the device) with a control group (participants not having the device) to see if the device works well.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Victoria
-
Fitzroy、Victoria、オーストラリア、3065
- St. Vincent's Private Hospital
-
Melbourne、Victoria、オーストラリア、3050
- Royal Melbourne Hospital
-
North Melbourne、Victoria、オーストラリア、3051
- Australian Prostate Centre
-
Richmond、Victoria、オーストラリア、3121
- Epworth HealthCare
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Men of ages between 30-70 years;
- Men with indication for nerve-sparing prostatectomy surgery;
- Localised prostate cancer considered suitable for bilateral nerve sparing prostatectomy according to clinical criteria
- International Index of Erectile Function (IIEF-15) erectile function domain score equal to or greater than 26 prior prostatectomy;
- Men interested in minimizing the effect of radical prostatectomy on erectile function;
- Ability to read and understand patient information materials and willingness to sign a written informed consent.
Exclusion Criteria:
- Men with neurological disease, including a history of spinal cord injury or trauma;
- IIEF-15 erectile function domain score less than 26 prior prostatectomy;
- Failure to demonstrate adequate nocturnal erectile function prior prostatectomy;
- History of erectile dysfunction, priapism and Peyronie disease;
- History of previous pelvic surgery, trauma or irradiation therapy;
- Currently have an active implantable device;
- Patient diagnosed with neurologic degenerative diseases that may negatively impact erectile functions;
- Identification of technical or clinical limitation to properly apply the use of nerve-sparing techniques during operation;
- Inability to understand and demonstrate device use instructions;
- Patients with insulin-dependent diabetes who suffer peripheral neuropathy or other diabetes associated complications;
- Patient unwillingness to engage in sexual activity;
- Patient is currently participating in another clinical investigation that would serve as a contraindication to implant a neurostimulator device to augment erectile function;
- Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other drug or device study during the next 24 months;
- Possess any other characteristics that, per the investigator's judgment, may increase the risk or impair data collection for the procedure/study;
- Patient is a member of a vulnerable population (Vulnerable participants include those who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, and employee volunteers).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Implanted group
The study device will be implanted during the ongoing prostatectomy surgery. Participants will then be asked to activate it everyday. |
The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function. |
|
介入なし:Control group
Participants in the control group will undergo standard prostatectomy and will not be implanted with the study device. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Occurrence of adverse events
時間枠:6 months
|
Adverse events will be reported using MedDRA terminology. |
6 months
|
|
Occurrence of surgical complications
時間枠:6 months
|
Surgical complications will be ranked according to the Clavien-Dindo classification |
6 months
|
|
Occurrence of device deficiencies
時間枠:6 months
|
Device deficiencies will be systematically reported and recorded. |
6 months
|
|
Pain
時間枠:6 months
|
Patients will be asked to rate pain on a visual analog scale (from 0 to 10) |
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Device effectiveness
時間枠:6 months
|
Erectile response obtained when activating the study device will be objectively assessed by measuring penile rigidity with the RigiScan device. |
6 months
|
|
Subjective Device effectiveness
時間枠:6 months
|
Erectile function will be subjectively assessed by asking participants to complete validated questionnaires (International Index of Erectile Function, IIEF-15 and Erection Hardness Score, EHS). |
6 months
|
|
Erectile function recovery
時間枠:6 months
|
Nocturnal penile erections will be assessed with the RigiScan device. Nocturnal erections reflect the extent of recovery of natural erectile function. |
6 months
|
|
Delineation of the surgical implantation procedure
時間枠:6 months
|
The surgeon will record information related to the implantation (duration, position of the device, grading ease of implantation steps, and any comments). |
6 months
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CP-1.5400
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。